trending Market Intelligence /marketintelligence/en/news-insights/trending/qo4yPLFtSA8uznphvA9yXg2 content esgSubNav
In This List

Celltrion Healthcare seeking up to 799.6B South Korean won in IPO

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Celltrion Healthcare seeking up to 799.6B South Korean won in IPO

Celltrion Healthcare Co. Ltd. expects to raise up to 799.6 billion South Korean won in an IPO of 24,604,000 shares priced at between 32,500 won and 41,000 won, Reuters reported.

Celltrion Healthcare is a marketing affiliate of Celltrion Inc. and exclusively sells the company's biosimilar drugs. The IPO on the junior KOSDAQ market will help the company forge its sales networks abroad and diversify its product portfolio.

The IPO is expected to be priced by July 17, with UBS and Mirae Asset Daewoo acting as advisers.

As of June 6, US$1 was equivalent to 1,119.04 South Korean won.